These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 20170027)

  • 1. [Update on new antithrombotic treatments].
    Boehlen F; Tirefort-Dimitrova Y; de Moerloose P; Fontana P
    Rev Med Suisse; 2010 Jan; 6(232):109-12. PubMed ID: 20170027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments.
    Mega JL; Simon T
    Lancet; 2015 Jul; 386(9990):281-91. PubMed ID: 25777662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antithrombotic drugs in vascular medicine: a historical perspective.
    Schrör K
    Semin Vasc Med; 2003 May; 3(2):97-105. PubMed ID: 15199472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anticoagulants of primary haemostasis].
    Kössler J; Steigerwald U; Walter U
    Hamostaseologie; 2009 Aug; 29(3):274-8. PubMed ID: 19644598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New anticoagulant drugs: monitoring and perioperative strategies.
    Ickx BE
    Acta Anaesthesiol Belg; 2006; 57(4):409-18. PubMed ID: 17236644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New anticoagulants].
    Levi M; Peters RJ; Piek JJ; Büller HR
    Ned Tijdschr Geneeskd; 2003 May; 147(19):909-15. PubMed ID: 12768805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New antithrombotic drugs.
    Gross PL; Weitz JI
    Clin Pharmacol Ther; 2009 Aug; 86(2):139-46. PubMed ID: 19553932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of antithrombotic drugs in coronary artery disease.
    Fauler J
    Ther Adv Cardiovasc Dis; 2009 Dec; 3(6):465-78. PubMed ID: 19726525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current and future antithrombotic therapies].
    Uzan A
    Ann Pharm Fr; 1996; 54(1):8-20. PubMed ID: 8702195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ticagrelor and thienopyridine P2Y(12) binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis.
    van Giezen JJ; Berntsson P; Zachrisson H; Björkman JA
    Thromb Res; 2009 Nov; 124(5):565-71. PubMed ID: 19692114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs.
    Gachet C
    Pharmacol Ther; 2005 Nov; 108(2):180-92. PubMed ID: 15955565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limitations of current therapies to prevent thrombosis: a need for novel strategies.
    Fabre JE; Gurney ME
    Mol Biosyst; 2010 Feb; 6(2):305-15. PubMed ID: 20094648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New antiplatelet agents.
    Spectre G; Varon D
    Curr Opin Hematol; 2009 Sep; 16(5):365-70. PubMed ID: 19587588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of bleeding in patients using antithrombotic agents: prediction, prevention, protection and problem-oriented intervention.
    Scharf RE
    Hamostaseologie; 2009 Nov; 29(4):388-98. PubMed ID: 19882082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
    Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
    Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet P2 receptors: old and new targets for antithrombotic drugs.
    Cattaneo M
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of current and future antithrombotic therapies.
    Müller TH; Binder K; Guth BD
    Cardiol Clin; 1994 Aug; 12(3):411-42. PubMed ID: 7805077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.